Delivery Order SPE2DB22D2206-SPE2DB23FKN32
- Not listed
- This federal contract award is for the delivery of Biktarvy 50-200-25 mg tablets to the Defense Logistics Agency (DLA), a component of the Department of Defense. The contract has a ceiling value of $10,728.19 and was awarded to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order with a firm fixed-price pricing type and has an ultimate completion date of March 7, 2024. There is no set-aside designation for this contract....
- This federal contract award is for the delivery of Biktarvy 50-200-25 mg tablet in 30-count packages to the Defense Logistics Agency (DLA). The contract, valued at $92,775.72, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a delivery order with a firm fixed price, and the ultimate completion date is June 8, 2023. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the...
- This federal contract award is for the pharmaceutical product Biktarvy 50-200-25 mg tablet, with a ceiling value of $74,022.59. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA), a defense agency. The contract is a delivery order, with a firm fixed-price pricing type, and does not have a set-aside designation. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery...
- This federal contract award is for the delivery of Biktarvy, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $19,159.33 and an ultimate completion date of October 30, 2024. It is a delivery order contract with a firm fixed-price pricing type. The contract was not designated with any set-aside...
- This federal contract award is for the delivery of Biktarvy 50-200-25 mg tablet pharmaceuticals to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $21,257.82, is a firm fixed-price delivery order with no set-aside designation. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award is for the delivery of Biktarvy 50-200-25 mg tablet, a prescription medication, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on November 24, 2021, with a ceiling value of $38,474.32 and a completion date of November 26, 2021. The contract is a firm fixed-price delivery order and does not have a set-aside designation, indicating...
- This federal contract award is for the delivery of Biktarvy 50-200-25 mg tablet, a pharmaceutical product, to the Defense Logistics Agency (DLA) Medical. The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract has a ceiling value of $23,197.99 and is a delivery order with a firm fixed price type. The contract has an ultimate completion date of May 11, 2023, and was awarded on May 10, 2023. The contract is...
- This federal contract award is for the delivery of Biktarvy 50-200-25 mg tablets to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for $82,631.52. The contract has an ultimate completion date of April 28, 2023 and is a firm fixed-price delivery order with no set-aside designation. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999 Indefinite...
- This federal contract award is for the delivery of pharmaceutical products, specifically Biktarvy 50-200-25 mg tablets, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on December 22, 2022, with a ceiling value of $6,178.43 and a completion date of December 23, 2022. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's...
- This federal contract award is for the delivery of Biktarvy 50-200-25 mg tablets to the Defense Logistics Agency (DLA). The $7,633.73 firm-fixed-price delivery order was awarded to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has an ultimate completion date of November 7, 2023 and was not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB23FKN32Delivery Order
This federal contract award is for the delivery of Biktarvy 50-200-25 mg tablet, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract has a ceiling value of $49,102.44 and was awarded to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of September 26, 2023. The contract is not associated with a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $49.1k | 9/25/23 |